(Reuters) -Shares in Valneva slumped around 25% on Monday after the French drugmaker said the United States Food and Drug ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing ...

U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...